11 April 2017 - Australian biotech OncoSil ­yesterday warned that because of domestic regulations local ­patients would have to wait a year longer than Europeans for access to its new pancreatic ­cancer treatment.

The Australian-listed company is pushing ahead with ­European approval for its device, which provides radiation therapy to diseased cells through ­material implanted in the affected organ.

OncoSil chief financial officer Tom Milicevic said once approval to market the device in Europe had been secured, the company would have to go through an 18-month approval process in Australia.

Read The Australian article